Details of Disease

General Information of Disease (ID: DISGGVL1)

Disease Name Fungal infection
Disease Class 1F29-1F2F: Fungal infection
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DISGGVL1: Fungal infection
ICD Code
ICD-11
ICD-11: 1F29-1F2F
ICD-10
ICD-10: B35-B49
ICD-9
ICD-9: 110-118
Expand ICD-9
1.10E+26
Disease Identifiers
MONDO ID
MONDO_0000256
UMLS CUI
C0553576
MedGen ID
639956
SNOMED CT ID
399314004

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 29 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Acrisorcin DM3D0FN Approved Small molecular drug [1]
Amphotericin B DMTAJQE Approved Small molecular drug [2]
Atovaquone DMY4UMW Approved Small molecular drug [3]
Benzoic Acid DMKB9FI Approved Small molecular drug [4]
Bifonazole DM3KN7V Approved Small molecular drug [5]
Caspofungin DMGQIPT Approved Small molecular drug [6]
Chlorphenesin DM3VZJQ Approved Small molecular drug [1]
Ciclopirox DMN5T2A Approved Small molecular drug [7]
Clotrimazole DMMFCIH Approved Small molecular drug [8]
Cupric Chloride DMFKYU5 Approved Small molecular drug [1]
Cupric Sulfate DMP0NFQ Approved Small molecular drug [1]
Eberconazole DMJ7RC9 Approved Small molecular drug [1]
Efinaconazole DMFA9MV Approved Small molecular drug [9]
Fluconazole DMOWZ6B Approved Small molecular drug [10]
Flutrimazole DMMR57T Approved Small molecular drug [1]
Fosfluconazole DMJFSRH Approved Small molecular drug [1]
Ibrexafungerp DMK1IPV Approved Small molecular drug [11]
Interferon gamma-n1 DMWZHHM Approved NA [1]
Itraconazole DMCR1MV Approved Small molecular drug [12]
Ketoconazole DMPZI3Q Approved Small molecular drug [13]
Liranaftate DMV6TL2 Approved Small molecular drug [1]
Mepartricin DMVAYKU Approved NA [1]
Miconazole DMPMYE8 Approved Small molecular drug [14]
Nystatin DM63QS9 Approved Small molecular drug [15]
Pentamidine DMHZJCG Approved Small molecular drug [16]
Sertaconazole DM1A9XO Approved Small molecular drug [17]
Sulconazole DM2SDUF Approved Small molecular drug [1]
Terbinafine DMI6HUW Approved Small molecular drug [18]
Thymol DMR7RL2 Approved Small molecular drug [19]
------------------------------------------------------------------------------------
⏷ Show the Full List of 29 Drug(s)
This Disease is Treated as An Indication in 13 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
BAL-8557 DMA72I1 Phase 3 Small molecular drug [20]
SPK-843 DMGQXCA Phase 3 NA [21]
Albaconazole DME4LVM Phase 2 Small molecular drug [22]
CZEN-002 DMUDMHA Phase 2 Small molecular drug [23]
E-1224 DMLS269 Phase 2 Small molecular drug [24]
EcoNail DM1LDIP Phase 2 Small molecular drug [25]
F901318 DM2CUS0 Phase 2 Small molecular drug [26]
Icofungipen DMTXNZK Phase 2 Small molecular drug [27]
NPH-30907 DMAJAQK Phase 2 NA [28]
Rilopirox DM3L51O Phase 2 Small molecular drug [29]
AN-2718 DM8B2WQ Phase 1 NA [30]
Embeconazole DM6AMKZ Phase 1 Small molecular drug [31]
Genaconazole DMWR93D Phase 1 Small molecular drug [32]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 Drug(s)
This Disease is Treated as An Indication in 19 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Abafungin DM09GSW Discontinued in Phase 3 Small molecular drug [33]
Panimun Bioral DMJ1VPJ Discontinued in Phase 3 Small molecular drug [34]
Saperconazole DMC57JU Discontinued in Phase 2 Small molecular drug [35]
ZD-0870 DM31FN4 Discontinued in Phase 2 Small molecular drug [36]
DUP-860 DMFCQUV Discontinued in Phase 1 Small molecular drug [37]
Anti-MRSA DMNP3UD Terminated NA [41]
BMS-181184 DM1Y75C Terminated Small molecular drug [42]
CAN-296 DMPU3TM Terminated NA [43]
Cepacidine A DMF76QP Terminated NA [44]
FR-901469 DM8BFSV Terminated NA [45]
LY-307853 DM18YVU Terminated NA [46]
Mycoprex DM6ANY7 Terminated NA [47]
R-102557 DMIS053 Terminated Small molecular drug [48]
Ro-23-7777 DM7B2WH Terminated NA [49]
RWJ-49815 DMUGZMO Terminated Small molecular drug [50]
SDZ-280-636 DMQN7GG Terminated NA [51]
TAN-950A DMAJY1Q Terminated Small molecular drug [52]
UR-9650 DM05XW1 Terminated NA [53]
UR-9660 DMQQYJX Terminated NA [54]
------------------------------------------------------------------------------------
⏷ Show the Full List of 19 Drug(s)
This Disease is Treated as An Indication in 5 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Cruentaren DM8AR0E Preclinical NA [38]
FAS1 DMAX2EW Preclinical NA [39]
FG-3622 DMX7LCW Preclinical NA [40]
FSA2 DMLNRCI Preclinical NA [39]
Indol-3-carbinol DMXJO20 Preclinical Small molecular drug [38]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 23 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Aminocandin DMH2RCJ Investigative NA [55]
BDM-I DM52B8E Investigative NA [55]
DWJ-205 DMMUEQD Investigative NA [55]
E-1210 DMH0K90 Investigative NA [55]
Echinocandin DMY4ZIV Investigative NA [55]
EV-086 DMTOAJB Investigative NA [55]
IB-07A085 DM40955 Investigative NA [55]
Intra-oral lozenge DMJ2OPJ Investigative NA [55]
JBD-201 DMA5GT1 Investigative NA [55]
LB-2.1 DMPPADS Investigative NA [55]
LTX-200 DMYSMXA Investigative NA [55]
MNT-03-01 DMQAMCV Investigative NA [55]
PB-200a DMD1VP8 Investigative NA [55]
PMX-10098 DMK4RW5 Investigative NA [55]
Pyridobenzimidazole DM3PAS4 Investigative Small molecular drug [38]
RLP-068 DM9T7L1 Investigative NA [55]
RWJ-49968 DMBOSGN Investigative NA [56]
RWJ-61907 DMGUWFJ Investigative NA [56]
SLP-1002 DMBB07U Investigative NA [55]
SOM-0633 DMFZI6U Investigative NA [55]
SOM-1000 DMB8Z7A Investigative NA [55]
VLF-02 DME4F4P Investigative NA [55]
VR-461 DMGM8V9 Investigative NA [55]
------------------------------------------------------------------------------------
⏷ Show the Full List of 23 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050724.
3 The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4565).
5 Drug information of Bifonazole, 2008. eduDrugs.
6 Echinocandins: pharmacokinetic and therapeutic issues. Curr Med Res Opin. 2009 Jul;25(7):1741-50.
7 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076435.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2330).
9 Efinaconazole: Developmental and reproductive toxicity potential of a novel antifungal azole. Reprod Toxicol. 2015 Apr;52:18-25.
10 Fluconazole use as an important risk factor in the emergence of fluconazole-resistant Candida glabrata fungemia. Arch Intern Med. 2009 Aug 10;169(15):1444-5; author reply 1445.
11 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031918)
12 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076104.
13 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2568).
14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2449).
15 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 062124.
16 Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
17 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021385.
18 Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manag. 2005 Dec;1(4):299-306.
19 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2499).
20 ClinicalTrials.gov (NCT00412893) Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis. U.S. National Institutes of Health.
21 ClinicalTrials.gov (NCT01125644) Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis. U.S. National Institutes of Health.
22 ClinicalTrials.gov (NCT00730405) Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis. U.S. National Institutes of Health.
23 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018001)
24 ClinicalTrials.gov (NCT01489228) Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease. U.S. National Institutes of Health.
25 ClinicalTrials.gov (NCT00385502) A Trial of the Safety and Efficacy of EcoNail in the Treatment of Fungus Infections of the Great Toenail. U.S. National Institutes of Health.
26 ClinicalTrials.gov (NCT03583164) Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options (FORMULA-OLS). U.S. National Institutes of Health.
27 Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits. Antimicrob Agents Chemother. 2005 May;49(5):2084-92.
28 Clinical pipeline report, company report or official report of Piramal Healthcare Ltd.
29 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006112)
30 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019312)
31 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014655)
32 In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agent. Antimicrob Agents Chemother. 1990 Jun;34(6):980-4.
33 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022887)
34 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013069)
35 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003602)
36 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003379)
37 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003241)
38 Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
39 Identification of a novel cell binding site of periostin involved in tumour growth. Eur J Cancer. 2011 Sep;47(14):2221-9.
40 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030610)
41 Anti-MRSA drug use and antibiotic susceptibilities of MRSA at a university hospital in Japan from 2007 to 2011. J Antibiot (Tokyo). 2013 May;66(5):273-6.
42 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005328)
43 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008980)
44 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007229)
45 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010934)
46 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008534)
47 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012746)
48 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014652)
49 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003620)
50 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009390)
51 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001044)
52 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003173)
53 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003909)
54 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003640)
55 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
56 Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9.
57 Clinical pipeline report, company report or official report of Pfizer.